<DOC>
	<DOC>NCT01618266</DOC>
	<brief_summary>Epidemiological study of Ozurdex® in sites treating patients with retinal vein occlusion.</brief_summary>
	<brief_title>Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Macular oedema due to retinal vein occlusion Not living in metropolitan France</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>